John Charin Somberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John Charin Somberg has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Janos Molnar
American Institute of Therapeutics, Lake Bluff, IL 60044
22 shared publicationsVasant Ranade
Department of Chemistry, Academic Pharmaceuticals, Lake Bluff, IL, USA
6 shared publicationsIvana Cvetanovic
Division of Clinical Pharmacology, Rush University, Chicago, IL, USA
5 shared publicationsRichard A. Preston
Division of Clinical Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, USA
2 shared publicationsSandor Timar
2 shared publications- Steven J. Bailin
Division of Cardiovascular Medicine, University of Iowa Health Care , 200 Hawkins Drive, Iowa City, IA 52242, USA
2 shared publications
Latest Publications
- 5 August 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 257, 38-42
The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent
- 5 August 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 257, 38-42
The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent
- Open Access
- 1 October 2021
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 12 (5) , 269
Do We Serve a Need?
N/A Cardiol Res. 2021;12(5):269-269 doi: https://doi.org/10.14740/cr1324
- 1 October 2021
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 12 (5) , 269
Open AccessDo We Serve a Need?
N/A Cardiol Res. 2021;12(5):269-269 doi: https://doi.org/10.14740/cr1324
- Open Access
- 1 August 2021
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 12 (4) , 209
The QT Interval in Research
N/A Cardiol Res. 2021;12(4):209-209 doi: https://doi.org/10.14740/cr1280
- 1 August 2021
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 12 (4) , 209
Open AccessThe QT Interval in Research
N/A Cardiol Res. 2021;12(4):209-209 doi: https://doi.org/10.14740/cr1280
- 1 December 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 136, 164-165
Van Gogh and Digitalis
- 1 December 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 136, 164-165
Van Gogh and Digitalis
- 1 May 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (10) , 1596-1598
The Bretylium Saga: A Novel “Old Drug” for Cardiac Resuscitation
- 1 May 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (10) , 1596-1598
The Bretylium Saga: A Novel “Old Drug” for Cardiac Resuscitation
- Open Access
- 1 January 2020
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 11 (5) , 294-304
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
- 1 January 2020
- Published by Elmer Press, Inc. in Cardiology Research
- Vol. 11 (5) , 294-304
Open AccessModel-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion
- Open Access
- 14 February 2018
- Published by S. Karger AG in Cardiology
- Vol. 139 (3) , 202
Evaluating Serious Adverse Drug Reactions
The evaluation of serious adverse drug reactions and their relationship to a pharmacologic agent is a most difficult undertaking. Adverse outcomes occur often, especially in severely sick patients. Assessing an outcome and its association with a particular drug is problematic.
- 14 February 2018
- Published by S. Karger AG in Cardiology
- Vol. 139 (3) , 202
Open AccessEvaluating Serious Adverse Drug Reactions
The evaluation of serious adverse drug reactions and their relationship to a pharmacologic agent is a most difficult undertaking. Adverse outcomes occur often, especially in severely sick patients. Assessing an outcome and its association with a particular drug is problematic.
- Open Access
- 14 June 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (7) , 779-784
Issue Information
- 14 June 2016
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (7) , 779-784
Open AccessIssue Information
- 1 November 2015
- Published by Elsevier in The American Journal of Cardiology
- Vol. 116 (9) , 1457-1460
Evaluation of the Effects of Different Energy Drinks and Coffee on Endothelial Function
- 1 November 2015
- Published by Elsevier in The American Journal of Cardiology
- Vol. 116 (9) , 1457-1460
Evaluation of the Effects of Different Energy Drinks and Coffee on Endothelial Function
- 1 September 2015
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 22 (5) , 342-349
Retrospective Evaluation on the Analgesic Activities of 2 Compounded Topical Creams and Voltaren Gel in Chronic Noncancer Pain
Pharmacologic treatment of chronic pain is challenging. Oral therapy may require multiple medications; each has side effects, dose limitations, and limited efficacy. Compounded topical formulations have evolved as potential treatment options. The objective of this study was to evaluate the efficacy of 2 compounded topical creams, "Cream I" and "Cream II," in patients with chronic extremity, joint, musculoskeletal, neuropathic, or other chronic topical pain conditions and compare their efficacy with Voltaren gel. The primary efficacy outcome was the change in visual numeric pain intensity score from pretreatment to posttreatment. The Cream I contained Flurbiprofen (20%), Tramadol (5%), Clonidine (0.2%), Cyclobenzaprine (4%), and Bupivacaine (3%). The Cream II contained Flurbiprofen (20%), Baclofen (2%), Clonidine (0.2%), Gabapentin (10%), and Lidocaine (5%). The Voltaren gel contained 1% diclofenac sodium. A total of 2177 patients were evaluated, 826 males and 1351 females. During their medical treatment, 1141 patients received Cream I, 527 patients received Cream II, and 509 patients received Voltaren gel. After treatment, the pain intensity score decreased by 3.11 +/- 1.65 (37%) with Cream I (from 8.44 +/- 1.19 to 5.33 +/- 2.0, P < 0.001), by 2.93 +/- 1.58 (35%) with Cream II (from 8.42 +/- 1.27 to 5.50 +/- 1.96, P < 0.001), and by 1.49 +/- 0.73 (19%) with Voltaren gel (from 7.93 +/- 0.81 to 6.44 +/- 1.14, P < 0.001). Cream I and Cream II did not differ significantly in efficacy, and both were significantly more effective than Voltaren gel (P < 0.001). It is concluded that Voltaren gel had less efficacy than the compounded creams, which were effective and provided pain relief in the majority of the patients studied.
- 1 September 2015
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 22 (5) , 342-349
Retrospective Evaluation on the Analgesic Activities of 2 Compounded Topical Creams and Voltaren Gel in Chronic Noncancer Pain
Pharmacologic treatment of chronic pain is challenging. Oral therapy may require multiple medications; each has side effects, dose limitations, and limited efficacy. Compounded topical formulations have evolved as potential treatment options. The objective of this study was to evaluate the efficacy of 2 compounded topical creams, "Cream I" and "Cream II," in patients with chronic extremity, joint, musculoskeletal, neuropathic, or other chronic topical pain conditions and compare their efficacy with Voltaren gel. The primary efficacy outcome was the change in visual numeric pain intensity score from pretreatment to posttreatment. The Cream I contained Flurbiprofen (20%), Tramadol (5%), Clonidine (0.2%), Cyclobenzaprine (4%), and Bupivacaine (3%). The Cream II contained Flurbiprofen (20%), Baclofen (2%), Clonidine (0.2%), Gabapentin (10%), and Lidocaine (5%). The Voltaren gel contained 1% diclofenac sodium. A total of 2177 patients were evaluated, 826 males and 1351 females. During their medical treatment, 1141 patients received Cream I, 527 patients received Cream II, and 509 patients received Voltaren gel. After treatment, the pain intensity score decreased by 3.11 +/- 1.65 (37%) with Cream I (from 8.44 +/- 1.19 to 5.33 +/- 2.0, P < 0.001), by 2.93 +/- 1.58 (35%) with Cream II (from 8.42 +/- 1.27 to 5.50 +/- 1.96, P < 0.001), and by 1.49 +/- 0.73 (19%) with Voltaren gel (from 7.93 +/- 0.81 to 6.44 +/- 1.14, P < 0.001). Cream I and Cream II did not differ significantly in efficacy, and both were significantly more effective than Voltaren gel (P < 0.001). It is concluded that Voltaren gel had less efficacy than the compounded creams, which were effective and provided pain relief in the majority of the patients studied.